The term “chronic kidney disease-mineral bone disorder (CKD-MBD)” replaced the older term “renal osteodystrophy” to more clearly convey the broad spectrum of sequelae that accompany abnormalities in blood levels of parathyroid hormone (PTH), calcium, and phosphate, the biochemical hallmarks of SHPT. The gene discussed is PTH; the disease is chronic kidney disease.